Case Report

Guillian-Barré Syndrome Following Vaccination with Covishield Vaccine: An Adverse Event of Special Interest


Several formulations of vaccines against novel coronavirus have been launched. Thereby, increasing the plausibility of having one or more successful vaccines. India put in place the world’s largest Covid-19 vaccination drive in January 2021. However, the side effects of these vaccines are slowly unfolding. Each new vaccine has potential adverse events of special interest (AESI) that warrant a focused evaluation. We report a very rare neurological complication Guillain-Barré syndrome, immediately following the first dose of COVID vaccination in a young female. An apparently healthy 35 years old female presented with acute onset lower backache, weakness of bilateral lower limbs 11 days after receiving the first dose of Covishield vaccine, which rapidly ascended to upper limbs over 5 days with symmetric motor weakness, power 1/5 in bilateral lower limbs, 3/5 in bilateral upper limbs, with absent deep tendon reflexes. Mild sensory involvement was seen. Evolving dysphagia and hoarseness of voice. Bladder/bowel function, respiratory pattern, and hemodynamics were unaffected. A provisional diagnosis of Guillain-Barre Syndrome was made on basis of clinical presentation, neurological examination, and nerve conduction studies suggesting axonal polyneuropathy. Gradual improvement of the muscle power over the next 2 weeks following Human Intravenous immunoglobulin was seen. The risk-benefit analysis for an individual should be considered prior to Covid-19 vaccination, including the implementation of a pre-vaccination screening checklist to ensure vaccine safety for every vaccine recipient. The vaccine continues to be far more beneficial than detrimental for the public at large. Nonetheless, increased awareness amongst healthcare professionals and the public regarding the potential adverse effects of the vaccine is warranted.

[1] The different types of COVID-19 vaccines.(n.d). Accessed: May 6:
[2] Li X, Ostropolets A, Makadia R, et al.: Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021; 373:n1435.
[3] Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process Manufacturer / WHO EUL holder Name of Vaccine NRA of Record Platform EOI accepted Pre-submission meeting held Dossier accepted for review* Status of assessment** Decision date***. (2022). Accessed: May 5:
[4] Kaur U, Ojha B, Pathak BK, Singh A, Giri KR, Singh A, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine. 2021. 38:101038.
[5] Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021. 384(22):2092-2101.
[6] Clinical Guidance for COVID-19 Vaccination | CDC. (n.d.). (2022). Accessed: May 5:
[7] Summary of Product Characteristics for Vaxzevria (n.d). (2022). Accessed: May 5:
[8] COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB. (n.d). (2021). Accessed: May 3:
[9] Martín Arias LH, Sanz R, Sáinz M, Sáinz M, Treceño C, Carvajal A. Guillain-Barré syndrome and influenza vaccines: A meta-analysis. Vaccine. 2015, 33(31):3773-8.
[10] van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10:469-82.
[11] Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 2020; 62:485-91.
[12] AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome. Reactions Weekly. 2021; 1864(1): 1.
[13] Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014; 137:33-43.
[14] Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol. 2021; 90:312-4.
[15] Prevaccination Checklist for COVID-19 Vaccines Information for Healthcare Professionals. (2022). Accessed: May 5:
[16] Lau CL, Galea I. Risk-benefit analysis of COVID-19 vaccines - a neurological perspective. Nature reviews. Neurology. 2022; 18:69-70.
[17] Li X, Raventós B, Roel E, et al.: Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ. 2022; 376:068373.
IssueVol 9 No 4 (2023): Autumn QRcode
SectionCase Report(s)
Clinical trial Acute Inflammatory Demyelinating Polyneuropathy Neurological Coronavirus Awareness

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Chauhan R, Bose A, R L. Guillian-Barré Syndrome Following Vaccination with Covishield Vaccine: An Adverse Event of Special Interest. Arch Anesth & Crit Care. 2023;9(4):360-365.